MatthewD.VolmMD

PubMed

• 57 citations
  Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
  Jasmeet Chadha Singh, Yelena Novik, Stacey Stein, Matthew Volm, M Meyers, Julia Smith, Coral Omene, James L. Speyer, Robert J. Schneider, Komal Jhaveri, Silvia C. Form...> ;Breast Cancer Research. 2014 Mar 31
• Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
  Singh JC, Stein S, Volm M, Smith JA, Novik Y, Speyer JL, Adams S, Meyers MI, Muggia F, Schneider R, Formenti S, Davis S, Choi H, Tiersten A> ;J. Clin. Oncol.. 2011-09-20
• Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromata...
  Dickler MN, Schneider BP, Volm M, Speyer JL, Novik Y, Callahan LA, Darby CH, Barth J, Elfring GL, Ogden A, Tiersten A> ;J. Clin. Oncol.. 2011-05-20
• 25 citations
  Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast ...
  Eleni Andreopoulou, Darci Gaiotti, Eugene Kim, Matthew Volm, Ruth Oratz, Robin S. Freedberg, Andrea Downey, Charles L. Vogel, Stephen Chia, Franco M. Muggia> ;Clinical Breast Cancer. 2007 Aug 1
• 24 citations
  Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon Progression
  Jonathan D. Schwartz, Max Sung, Myron Schwartz, Deborah Lehrer, John Mandeli, Leonard Liebes, Alec Goldenberg, Matthew Volm> ;The Oncologist. 2005 Oct 1
• A phase II trial of DTIC with thalidomide (thal) in metastatic melanoma (MM).
  Fink M, Pavlick AC, Bailes A, Farrell K, Volm M, Oratz R, Muggia F> ;J. Clin. Oncol.. 2004-07-15
• Thalidomide (Thal) tolerance in patients treated with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
  Goldenberg A, Volm M, Hochster H, Muggia F, Rosen R, Teperman L, Morgan G, Schwartz J, Sung M, Wadler S> ;J. Clin. Oncol.. 2004-07-15
• 4 citations
  Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
  Missak Haigentz, Mimi Kim, Joan Sorich, Janet Lee, Howard S. Hochster, Manuel Macapinlac, Deepu Mirchandani, Sanjeev Sewak, Anna C. Pavlick, Matthew Volm, Anne Hamilto...> ;Anti-Cancer Drugs. 2003 Apr 1
• 90 citations
  Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast ...
  Silvia C. Formenti, Matthew Volm, Kristin A. Skinner, Darcy V. Spicer, Deidre Cohen, Edith A. Perez, Anna Cecilia Bettini, S. Groshen, Conway Gee, Barbara D. Florentin...> ;Journal of Clinical Oncology. 2003 Mar 1
• 20 citations
  Male breast cancer.
  Matthew Volm> ;Current Treatment Options in Oncology. 2003 Apr 1
• Protein expression profiles indicative for drug resistance of non-small cell lung cancer.
  Volm M, Koomägi R, Mattern J, Efferth T> ;Br. J. Cancer. 2002-07-29
• Protein expression profile of newly diagnosed acute lymphoblastic leukemia in children developing relapses.
  Volm M, Sauerbrey A, Zintl F, Koomägi R, Efferth T> ;Oncol. Rep.. 2002-01-01
• Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain react...
  Koomagi R, Zintl F, Sauerbrey A, Volm M> ;Clin. Cancer Res.. 2001-11-01
• 242 citations
  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
  Sandra Demaria, Matthew Volm, Richard L. Shapiro, Herman Yee, Ruth Oratz, Silvia C. Formenti, Franco M. Muggia, W. F. Symmans> ;Clinical Cancer Research. 2001 Oct 1
• 60 citations
  Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy
  Beata Holkova, Kenichi Takeshita, Debbie M. Cheng, Matthew Volm, Carolyn Wasserheit, Rita I. Demopoulos, Asher Chanan-Khan> ;Journal of Clinical Oncology. 2001 Sep 15
• 17 citations
  Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer
  Anne Hamilton, Matthew Volm> ;Oncology. 2001 Aug 1
• Clinical estimation of the growth rate of lung cancer.
  Mattern J, Volm M> ;Anticancer Res.. 2001-01-01
• 115 citations
  Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant t...
  W. Fraser Symmans, Matthew Volm, Richard L. Shapiro, A. Bridget Perkins, Alice Y. Kim, Sandra Demaria, Herman T. Yee, Heather F. McMullen, Ruth Oratz, Paula Klein, Sil...> ;Clinical Cancer Research. 2000 Dec 1
• Angiostatin expression in non-small cell lung cancer.
  Volm M, Mattern J, Koomägi R> ;Clin. Cancer Res.. 2000-08-01
• Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
  Volm M, Koomägi R> ;Br. J. Cancer. 2000-05-01
• nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma.
  Schneider J, Pollán M, Jiménez E, Marenbach K, Martínez N, Volm M, Marx D, Meden H> ;Br. J. Cancer. 2000-05-01
• Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer.
  Volm M, Koomagi R> ;Oncol. Rep.. 2000-01-01
• Association of telomerase expression with successful heterotransplantation of lung cancer.
  Volm M, Mattern J, Koomägi R> ;Int. J. Oncol.. 2000-01-01
• Cellular predictive factors for the drug response of lung cancer.
  Volm M, Rittgen W> ;Anticancer Res.. 2000-01-01
• Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer.
  Volm M, Koomägi R> ;Anticancer Res.. 2000-01-01
• Join now to see all